🇺🇸 FDA
Pipeline program

Dexmedetomidine-esketamine combination

2023-276

Unknown small_molecule completed

Quick answer

Dexmedetomidine-esketamine combination for Liver Cancer is a Unknown program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Liver Cancer
Phase
Unknown
Modality
small_molecule
Status
completed

Clinical trials